MIRA
INFORM REPORT
|
Report Date : |
03.06.2008 |
IDENTIFICATION
DETAILS
|
Name : |
CAPSUGEL JAPAN INC |
|
|
|
|
Registered Office : |
4-3-36 Minamihashimoto Sagamihara City Kanagawa-Pref 229-1133 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
30.11.2007 |
|
|
|
|
Date of Incorporation : |
December 2001 |
|
|
|
|
Legal Form : |
Limited Company (Kabushiki Kaisha) |
|
|
|
|
Line of Business : |
Manufacturer of
Pharmaceutical Capsules, Capsule Filling Machines |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
YEN 115.5 Million |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
name & address
CAPSUGEL JAPAN INC
REGD NAME: Capsugel Japan KK
MAIN OFFICE: 4-3-36
Minamihashimoto Sagamihara City Kanagawa-Pref 229-1133 JAPAN
Tel:
0427-70-4600 Fax: 0427-71-7397
URL: http://www.capsugel-jp.com
E-Mail address:marketingCJ@pfizer.com
ACTIVITIES
Mfg pharmaceutical capsules, capsule filling machines
BRANCHES
Nil
FACTORY(IES)
At the caption address
OFFICERS
Hiromitsu Iwasaki, ch
EISAKU SAI, PRES
G Dreesen, dir (phonetically spelled)
Hirokane Kyoyama, dir
Hiroshi Toda, dir
Yen Amount
In million Yen, unless otherwise stated
SUMMARY
FINANCES FAIR A/SALES Yen 6,500 M
PAYMENTS REGULAR CAPITAL Yen 310 M
TREND STEADY WORTH Yen 2,498 M*
STARTED 2001 EMPLOYES 150
*.. Estimated figures only as full financials are not made
available.
COMMENT
MFR OF
CAPSULES FOR PHARMACEUTICAL INDUSTRIES, WHOLLY OWNED BY PFIZER JAPAN INC.
FINANCIAL
SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.
MAX CREDIT LIMIT
YEN 115.5 MILLION, 30 DAYS NORMAL TERMS. .
HIGHLIGHTS
The subject company was established as Japan Warner Lambert KK at the caption Address for mfg capsules and capsule filling machines for the pharmaceutical industries. After merger and reorganization, the firm was renamed as captioned and joined Pfizer Inc group. Wholly owned by Pfizer Japan Inc. Hiromitsu Iwasaki is concurrently pres of the Japan parent.
FINANCIAL INFORMATION
Financials are only partially disclosed and in rounded-off numbers. The firm says financials are consolidated by the parent, Pfizer Japan Inc. Profits are estimated as calculated from the pre-tax figures disclosed from the Taxation Office.
The sales volume for Nov/2007 fiscal term said amounted to Yen 6,500 million, a similar amount in the previous term. The net profit is believed posted at Yen 545 million, up from Yen 540 million in the previous year. The net worth is estimated by us only.
For the current term ending Nov 2008 the net profit is projected at Yen 550 million, on a 2% rise in turnover, to Yen 6,600 million. The firm does not disclose sales targets, etc and this is again only estimated by us.
The financial situation is considered maintained FAIR and good for ORDINARY business engagements. Max credit limit is estimated at Yen 115.5 million, on 30 days normal terms.
REGISTRATION
Date Registered: Dec 2001
Legal Status: Limited Company (Kabushiki Kaisha)
Authorized: 6,200 shares
Issued: 6,200 shares
Sum: Yen 310 million
Major shareholders (%)
Pfizer Japan Inc*(100)
*.. Pharmaceutical mfr, Tokyo, wholly owned by Pfizer Inc (USA), founded 1953, capital Yen 64,800 million, turnover Yen 415,000 million (Nov/2006 fiscal term), employees 6,091, pres Hiromitsu Iwasaki, concurrently
Nothing detrimental is known as to the commercial morality of executives.
OPERATION
Activities: Manufactures capsules, including hard gelatin, soft-gel, non-animal & fish gelatin capsules, liquid filling and sealing equipment, and the related (--100%).
Clients
Pharmaceutical mfrs, dietary supplement industry, wholesalers, drug stores, other
No. of accounts
1,000
Domestic areas of activities
Nationwide
Suppliers
[Mfrs, wholesalers] Nitta Gelatin, Hayashibara Shoji, other. Also supplied from Pfizer group firms in USA, etc.
Payment record
Regular
Location
Business area in Sagamihara City, Kanagawa-Pref. Office premises at the caption address are owned and maintained satisfactorily.
Bank References
Mizuho Bank (Hashimoto)
MUFG (Shinjuku-Fukutoshin)
Relations: Satisfactory
FINANCES: (In Million Yen)
|
Terms Ending: |
|
30/11/2008 |
30/11/2007 |
30/11/2006 |
30/11/2005 |
|
Annual
Sales |
|
6,600 |
6,500 |
6,500 |
6,500 |
|
Recur.
Profit |
|
|
|
|
|
|
Net
Profit |
|
550 |
545 |
540 |
544 |
|
Total
Assets |
|
|
N/A |
N/A |
N/A |
|
Net
Worth |
|
|
2,498 |
1,953 |
1,413 |
|
Capital,
Paid-Up |
|
|
310 |
310 |
310 |
|
Div.P.Share(¥) |
|
|
|
|
|
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
1.54 |
0.00 |
0.00 |
0.00 |
|
|
Current Ratio |
|
|
.. |
.. |
.. |
|
N.Worth Ratio |
|
.. |
.. |
.. |
|
|
N.Profit/Sales |
8.33 |
8.38 |
8.31 |
8.37 |
|
Note: Financials are only partially disclosed.
Forecast (or estimated) for the 30/11/2008 fiscal term.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)